GLL 398 is an orally active and selective degrader of estrogen receptor with an IC50 of 1.14 nM. GLL 398 blocks tumor growth in xenograft breast cancer models.

ER degrader 6 (compound 35s) is a potent selective estrogen receptor modulator (SERM) with the capacity to degrade Estrogen Receptor (ER)α. It disrupts the microtubule network, inhibiting tubulin polymerization, and effectively suppresses tumor growth with minimal toxicity [1].

Imlunestrant tosylate (LY-3484356) is a potent, orally active selective estrogen receptor degrader (SERD) exhibiting purely antagonistic properties. It effectively maintains inhibition of estrogen receptor (ER)-dependent gene transcription and inhibits cell growth. This compound is applicable in research on ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) [1] [2].

Elacestrant (RAD1901) with IC50s of 48 and 870 nM for ERα and ERβ, respectively.Elacestrant  is an orally available selective estrogen receptor degrader .

Elacestrant dihydrochloride (DA-DKRAD1901 dihydrochloride) is an orally available selective estrogen receptor degrader with IC50s of 48 for ERα and 870 nM for ERβ, respectively.

GNE-149 is an orally bioavailable compound that acts as a full antagonist of estrogen receptor α (ERα) with an IC50 of 0.053 nM. It is also classified as a selective estrogen receptor degrader (SERD). GNE-149 holds potential for research in the field of breast cancer.

ERα degrader-2 is a selective and potent estrogen receptor (SERD) degrader with anticancer activity, inhibits ERα, and has an EC50 value for estrogen receptor degradation of 0.3 nM.ERα degrader-2 can be used for the prevention and treatment of HER-positive breast cancer.

Elacestrant S enantiomer is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.

ER degrader 4, a selective and orally active compound, effectively degrades estrogen receptors and exhibits anti-tumor activity [1].

Imlunestrant is a selective, orally active estrogen receptor degrader (SERD) that can be used in ER+ and HER2 breast cancer studies.

AZD9496 maleate is a highly potent and selective antagonist of the estrogen receptor alpha (ERα), exhibiting an IC50 value of 0.28 nM. This compound, AZD9496 maleate, is an orally bioavailable selective estrogen receptor degrader (SERD).

Elacestrant (RAD1901) dihydrochloride is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant S enantiomer dihydrochloride is an low activity enantiomer of elacestrant dihydrochloride.

Amcenestrant (SAR439859) is an orally active, nonsteroidal and selective degrader of estrogen receptor (SERD). SAR439859 is a potent antagonist of ER (with an EC50 of 0.2 nM for ERα degradation).

Rintodestrant (G1T48) is an orally active, non-steroidal, selective estrogen receptor degrader (SERD) that also functions as a CDK4/6 inhibitor.

THIQ-40 is a novel potent erα antagonist and selective estrogen receptor degrader (serd), exhibiting good oral bioavailability, antitumor efficacy, and serd activity in vivo

LSZ-102 is an effective and selective degrader of estrogen receptor (IC50 = 0.2 nM) and can be used in studies about ERα positive breast cancer.

ERα degrader 5 is an orally active, selective estrogen receptor (ER) reducer that acts on ERα (EC50: 1.1 nM). ERα degrader 5 shows anti-tumour effects in vivo.

LX-039 is a potent, selective, orally active estrogen receptor degrader (EC50: 2.99 nM) with antitumor effects.LX-039 has indole C-3 chloride atoms.LX-039 has good pharmacokinetic properties in mice, low clearance, high blood levels and oral exposure.

Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research.

Taragarestrant (D-0502) meglumine is a potent, orally active, and selective estrogen receptor degrader (SERD) demonstrating significant efficacy in ER+ breast cancer cell lines and xenograft models [1] [2].

Brilanestrant (GDC-0810) is a selective estrogen receptor degrader (IC50: 0.7 nM).